At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NKTX Nkarta
Pre-Mkt 10-02 07:31:28 EDT
2.56
-0.06
-2.29%
盘前2.59
+0.03+1.17%
04:00 EDT
High2.67Low2.55Vol402.30K
Open2.59D1 Closing2.62Amplitude4.77%
Mkt Cap183.16MTradable Cap154.73MTotal Shares71.55M
T/O1.04MT/O Rate0.67%Tradable Shares60.44M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Nkarta (NKTX) Receives a Buy from Stifel Nicolaus
TIPRANKS  ·  09-28
Nkarta (NKTX) Receives a Buy from Stifel Nicolaus
H.C. Wainwright Reaffirms Their Buy Rating on Nkarta (NKTX)
TIPRANKS  ·  09-22
H.C. Wainwright Reaffirms Their Buy Rating on Nkarta (NKTX)
Nkarta to Participate in September Investor Conferences
GlobeNewswire  ·  09-10
Nkarta to Participate in September Investor Conferences
Nkarta to Present Initial Phase 1/2 Autoimmune Data for CAR-NK Therapy Nkx019 at ACR Convergence 2026
Reuters  ·  09-08
Nkarta to Present Initial Phase 1/2 Autoimmune Data for CAR-NK Therapy Nkx019 at ACR Convergence 2026
Mizuho Securities Sticks to Their Buy Rating for Nkarta (NKTX)
TIPRANKS  ·  08-18
Mizuho Securities Sticks to Their Buy Rating for Nkarta (NKTX)
Equillium Q2 Post Narrower Net Loss than Expected; Starts R&D Initiatives
Reuters  ·  08-14
Equillium Q2 Post Narrower Net Loss than Expected; Starts R&D Initiatives
NuCana Q2 Loss Narrows as Clinical Milestones Remain on Track
Reuters  ·  08-14
NuCana Q2 Loss Narrows as Clinical Milestones Remain on Track
Assembly Biosciences Q2 Net Loss Narrows as Revenue Rises
Reuters  ·  08-14
Assembly Biosciences Q2 Net Loss Narrows as Revenue Rises
Ovid Therapeutics Q2 Revenue Beats Estimates
Reuters  ·  08-13
Ovid Therapeutics Q2 Revenue Beats Estimates
Century Therapeutics Q2 Net Loss Misses Estimates on Lease Termination Loss
Reuters  ·  08-12
Century Therapeutics Q2 Net Loss Misses Estimates on Lease Termination Loss
Pliant Therapeutics Q2 Net Loss Narrows on Operating Expenses Decline, Reduced Headcount
Reuters  ·  08-12
Pliant Therapeutics Q2 Net Loss Narrows on Operating Expenses Decline, Reduced Headcount
Vor Biopharma Posts Wider-than-Expected Q2 Loss on Increased G&A Costs
Reuters  ·  08-11
Vor Biopharma Posts Wider-than-Expected Q2 Loss on Increased G&A Costs
Neurogene Q2 Adjusted Loss Per Share Misses Estimates on Employee Costs
Reuters  ·  08-11
Neurogene Q2 Adjusted Loss Per Share Misses Estimates on Employee Costs
Shattuck Labs Q2 Net Loss Widens as R&D Spending Rises
Reuters  ·  08-11
Shattuck Labs Q2 Net Loss Widens as R&D Spending Rises
Nkarta, Inc. : H.c. Wainwright Cuts Target Price to $14 from $16
THOMSON REUTERS  ·  08-11
Nkarta, Inc. : H.c. Wainwright Cuts Target Price to $14 from $16
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX) and Rocket Pharmaceuticals (RCKT)
TIPRANKS  ·  08-11
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX) and Rocket Pharmaceuticals (RCKT)
Nkarta, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-11
Nkarta, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
Nkarta Q2 EPS $(0.54) Misses $(0.38) Estimate
Benzinga Earnings  ·  08-11
Nkarta Q2 EPS $(0.54) Misses $(0.38) Estimate
Biotech Firm Nkarta Posts Q2 Net Loss; Cash Runway into 2029
Reuters  ·  08-11
Biotech Firm Nkarta Posts Q2 Net Loss; Cash Runway into 2029
Nkarta Q2 FY26 Net Loss Widens to $40.4 Million
Reuters  ·  08-11
Nkarta Q2 FY26 Net Loss Widens to $40.4 Million

Introduction

Company Name.
Nkarta
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a lymphocyte that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, that is in phase I for the treatment of various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Issue price:
--